Altimmune, Inc. (ALT)

Lumos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	183.11	36.93	135.12	111.1	190.3	115.92
Short-Term Investments	-	94.97	62.7	73.78	-	100.01
Cash & Short-Term Investments	183.11	131.89	197.82	184.88	190.3	215.92
Cash Growth	11.04%	-33.33%	7.00%	-2.85%	-11.87%	479.81%
Accounts Receivable	0.32	0.54	1.11	0.17	0.43	4.61
Other Receivables	0.56	2.57	3.74	2.37	5.41	7.76
Receivables	0.88	3.12	4.85	2.54	5.84	12.37
Prepaid Expenses	4.4	2.1	6.92	5.36	7.95	1.93
Restricted Cash	0.04	0.04	0.04	0.03	0.03	0.03
Other Current Assets	-	0.1	-	-	-	-
Total Current Assets	188.42	137.25	209.63	192.81	204.13	230.26
Property, Plant & Equipment	0.36	2.05	1.01	1.68	2.25	1.96
Other Intangible Assets	-	-	-	12.42	12.42	12.82
Other Long-Term Assets	1.56	-	-	0.02	0.07	0.07
Total Assets	190.35	139.31	210.64	206.93	218.87	245.12
Accounts Payable	0.85	0.21	2.07	4.8	2.03	0.61
Accrued Expenses	8.37	9.98	9.58	10.63	9.74	11.05
Current Portion of Leases	-	0.28	0.5	0.45	0.41	0.36
Current Income Taxes Payable	-	-	-	1.17	-	-
Other Current Liabilities	-	-	-	-	6.09	-
Total Current Liabilities	9.22	10.47	12.14	17.05	18.28	12.02
Long-Term Debt	14.33	-	-	-	-	-
Long-Term Leases	-	1.4	0.18	0.67	1.12	1.47
Long-Term Unearned Revenue	-	0.16	0.16	0.25	0.25	0.25
Other Long-Term Liabilities	5.43	3.77	4.06	3.66	0.08	5.5
Total Liabilities	28.98	15.8	16.54	21.64	19.73	19.24
Common Stock	0.01	0.01	0.01	0.01	0	0
Additional Paid-In Capital	769.51	689.86	665.43	568.4	497.34	417.34
Retained Earnings	-603.11	-561.39	-466.33	-377.88	-293.17	-186.42
Comprehensive Income & Other	-5.04	-4.97	-5	-5.23	-5.04	-5.04
Total Common Equity	161.37	123.51	194.1	185.29	199.14	225.88
Shareholders' Equity	161.37	123.51	194.1	185.29	199.14	225.88
Total Liabilities & Equity	190.35	139.31	210.64	206.93	218.87	245.12
Total Debt	14.33	1.68	0.67	1.12	1.54	1.82
Net Cash (Debt)	168.77	130.21	197.14	183.76	188.77	214.1
Net Cash Growth	3.51%	-33.95%	7.29%	-2.65%	-11.83%	503.16%
Net Cash Per Share	2.26	1.83	3.70	3.92	4.57	8.35
Filing Date Shares Outstanding	81.48	77.01	70.9	49.28	42.92	36.98
Total Common Shares Outstanding	81.48	72.35	70.68	49.2	40.69	36.97
Working Capital	179.2	126.79	197.48	175.76	185.85	218.24
Book Value Per Share	1.98	1.71	2.75	3.77	4.89	6.11
Tangible Book Value	161.37	123.51	194.1	172.87	186.72	213.05
Tangible Book Value Per Share	1.98	1.71	2.75	3.51	4.59	5.76
Machinery	-	0.7	0.7	0.65	1.55	1.31
Leasehold Improvements	-	1.75	1.75	1.75	1.79	1.29

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q